SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

Efe C, Tascilar K, Gerussi A, Bolis F, Lammert C, Ebik B, Stättermayer AF, Cengiz M, Gökçe DT, Cristoferi L, Peralta M, Massoumi H, Montes P, Cerda E, Rigamonti C, Yapalı S, Adali G, Çalışkan AR, Balaban Y, Eren F, Eşkazan T, Barutçu S, Lytvyak E, Zazueta GM, Kayhan MA, Heurgue-Berlot A, De Martin E, Yavuz A, Bıyık M, Narro GC, Duman S, Hernandez N, Gatselis NK, Aguirre J, Idilman R, Silva M, Mendizabal M, Atay K, Güzelbulut F, Dhanasekaran R, Montano-Loza AJ, Dalekos GN, Ridruejo E, Invernizzi P, Wahlin S (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 132

Article Number: 102906

DOI: 10.1016/j.jaut.2022.102906

Abstract

Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17–85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10–0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11–0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.

Authors with CRIS profile

Involved external institutions

Gülhane Training and Research Hospital / Gülhane Eğitim ve Araştırma Hastanesi (GEAH) Turkey (TR) Uludag University / Uludağ Üniversitesi Turkey (TR) Centre hospitalier universitaire de Reims (CHU de Reims) France (FR) Adıyaman Üniversitesi Turkey (TR) École Polytechnique - Université Paris-Saclay France (FR) Ankara University / Ankara Üniversitesi Turkey (TR) Hospital Central Militar Mexico / Central Military Hospital Mexico (MX) University of Eastern Piedmont / Università degli Studi del Piemonte Orientale "Amedeo Avogadro" Italy (IT) University of Milano-Bicocca / Università degli Studi di Milano-Bicocca, UNIMIB Italy (IT) Hospital Muñiz / Hospital de Infecciosas Francisco Javier Muñiz Argentina (AR) Harran Üniversitesi Turkey (TR) Ankara City Hospital / Ankara Şehir Hastanesi Turkey (TR) Diyarbakir Gazi Yasargil Education and Research Hospital Turkey (TR) Stanford University United States (USA) (US) Indiana University Health / Clarian Health Partners United States (USA) (US) Medizinische Universität Wien Austria (AT) Acıbadem Mehmet Ali Aydınlar University / Acıbadem Mehmet Ali Aydınlar Üniversitesi Turkey (TR) Mardin State Hospital Turkey (TR) University of Alberta Canada (CA) Hospital Nacional Daniel Alcides Carrión Peru (PE) General University Hospital of Larissa Greece (GR) Latin American Liver Research Educational and Awareness Network (LALREAN) Argentina (AR) Montefiore Medical Center United States (USA) (US) Hospital Angeles Pedregal Mexico (MX) Necmettin Erbakan Üniversitesi Turkey (TR) Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico (MX) Karolinska University Hospital / Karolinska Universitetssjukhuset Sweden (SE) Hacettepe University Turkey (TR) Umrani̇ye Training and Research Hospital / Ümraniye Eğitim ve Araştırma Hastanesi Turkey (TR) Gaziantep University / Gaziantep Üniversitesi Turkey (TR) İstanbul Eğitim ve Araştırma Hastanesi Turkey (TR) Istanbul University Cerrahpaşa / İstanbul Üniversitesi Cerrahpaşa (IUC) Turkey (TR) University of the Republic / Universidad de la República (UdelaR) Uruguay (UY)

How to cite

APA:

Efe, C., Tascilar, K., Gerussi, A., Bolis, F., Lammert, C., Ebik, B.,... Wahlin, S. (2022). SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis. Journal of Autoimmunity, 132. https://doi.org/10.1016/j.jaut.2022.102906

MLA:

Efe, Cumali, et al. "SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis." Journal of Autoimmunity 132 (2022).

BibTeX: Download